Health Canada's revised guidance on biosimilars this month
This article was originally published in Scrip
Executive Summary
Health Canada's revised guidance document on subsequent entry biologics (SEBs) is expected to contain new sections including one pertaining to "considerations for use of a non-Canadian reference product". The revised draft guidance document is to be released this month and will be open for comments.